DK0987256T3 - Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid - Google Patents

Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Info

Publication number
DK0987256T3
DK0987256T3 DK99117098T DK99117098T DK0987256T3 DK 0987256 T3 DK0987256 T3 DK 0987256T3 DK 99117098 T DK99117098 T DK 99117098T DK 99117098 T DK99117098 T DK 99117098T DK 0987256 T3 DK0987256 T3 DK 0987256T3
Authority
DK
Denmark
Prior art keywords
methylisoxazole
trifluoromethylphenyl
carboxylic acid
acid amide
crystal form
Prior art date
Application number
DK99117098T
Other languages
Danish (da)
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Erich Dr Paulus
Uwe Dr Westenfelder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0987256T3 publication Critical patent/DK0987256T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99117098T 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid DK0987256T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
DK0987256T3 true DK0987256T3 (da) 2002-02-11

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Country Status (28)

Country Link
US (5) US6060494A (cs)
EP (2) EP0903345B1 (cs)
JP (2) JPH11124372A (cs)
KR (2) KR100544041B1 (cs)
CN (2) CN1089759C (cs)
AR (1) AR015418A1 (cs)
AT (2) ATE196764T1 (cs)
AU (1) AU752764B2 (cs)
BR (1) BR9806568A (cs)
CA (1) CA2245267C (cs)
CZ (3) CZ301426B6 (cs)
DE (2) DE59801792D1 (cs)
DK (2) DK0987256T3 (cs)
ES (2) ES2166205T3 (cs)
GR (1) GR3034814T3 (cs)
HK (1) HK1049481B (cs)
HU (2) HU229232B1 (cs)
ID (1) ID20667A (cs)
IL (1) IL125671A (cs)
NO (1) NO310871B1 (cs)
NZ (1) NZ331270A (cs)
PL (1) PL192126B1 (cs)
PT (2) PT903345E (cs)
RU (1) RU2224753C2 (cs)
SK (2) SK285216B6 (cs)
TR (2) TR200600582A1 (cs)
TW (1) TW593288B (cs)
UA (1) UA54411C2 (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
SK8332002A3 (en) * 1999-12-16 2003-04-01 Teva Pharma Novel processes for making- and a new crystalline form of leflunomide
ATE292966T1 (de) * 2000-02-15 2005-04-15 Teva Pharma Methode zur synthetisierung von leflunomid
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
EA017064B1 (ru) * 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
RU2012115459A (ru) 2009-09-18 2013-10-27 Санофи Таблетируюмый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
ATE151633T1 (de) * 1990-05-18 1997-05-15 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden- cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9115377D0 (en) * 1991-07-17 1991-09-04 Rhone Poulenc Agriculture New compositions of matter
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124801T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
EP0607775B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
TW314467B (cs) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
NZ293691A (en) * 1994-10-17 1999-07-29 Hoechst Japan Use of a medicament containing an anilide compound for treatment of type i allergic diseases
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
SK8332002A3 (en) * 1999-12-16 2003-04-01 Teva Pharma Novel processes for making- and a new crystalline form of leflunomide
ATE292966T1 (de) * 2000-02-15 2005-04-15 Teva Pharma Methode zur synthetisierung von leflunomid
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
IL125671A0 (en) 1999-04-11
HUP9801844A3 (en) 2000-04-28
HU229232B1 (en) 2013-09-30
ES2150808T3 (es) 2000-12-01
KR19990023433A (ko) 1999-03-25
NO983632D0 (no) 1998-08-07
AU752764B2 (en) 2002-09-26
NO310871B1 (no) 2001-09-10
NO983632L (no) 1999-02-09
TR199801513A3 (tr) 1999-02-22
PT903345E (pt) 2001-01-31
TR200600582A1 (tr) 2006-08-21
EP0903345A1 (de) 1999-03-24
HK1049481B (zh) 2005-07-08
CA2245267A1 (en) 1999-02-08
ID20667A (id) 1999-02-11
AU7887098A (en) 1999-02-18
EP0987256B1 (de) 2001-10-17
DE59800287D1 (de) 2000-11-09
TR199801513A2 (xx) 1999-02-22
CZ301426B6 (cs) 2010-02-24
HUP9801844A2 (hu) 2000-02-28
SK285216B6 (sk) 2006-09-07
CZ246898A3 (cs) 1999-02-17
JPH11124372A (ja) 1999-05-11
KR100588254B1 (ko) 2006-06-12
HK1017681A1 (en) 1999-11-26
DK0903345T3 (da) 2000-10-23
EP0987256A1 (de) 2000-03-22
CN1208034A (zh) 1999-02-17
IL125671A (en) 2002-11-10
ES2166205T3 (es) 2002-04-01
US6221891B1 (en) 2001-04-24
CZ301514B6 (cs) 2010-03-31
CA2245267C (en) 2008-12-23
GR3034814T3 (en) 2001-02-28
HK1049481A1 (en) 2003-05-16
US20030027851A1 (en) 2003-02-06
EP0903345B1 (de) 2000-10-04
US6060494A (en) 2000-05-09
JP2009280604A (ja) 2009-12-03
PT987256E (pt) 2002-03-28
US20030166945A1 (en) 2003-09-04
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
SK282641B6 (sk) 2002-10-08
ATE196764T1 (de) 2000-10-15
CN1373126A (zh) 2002-10-09
CN1089759C (zh) 2002-08-28
RU2224753C2 (ru) 2004-02-27
HU9801844D0 (en) 1998-10-28
AR015418A1 (es) 2001-05-02
HU225870B1 (en) 2007-11-28
UA54411C2 (uk) 2003-03-17
CN1181064C (zh) 2004-12-22
US6552202B2 (en) 2003-04-22
KR100544041B1 (ko) 2006-09-18
ATE207065T1 (de) 2001-11-15
PL327901A1 (en) 1999-02-15
TW593288B (en) 2004-06-21
PL192126B1 (pl) 2006-09-29
CZ292943B6 (cs) 2004-01-14
SK105898A3 (en) 1999-02-11
BR9806568A (pt) 2000-05-16
DE59801792D1 (de) 2001-11-22
KR20050077498A (ko) 2005-08-02
HU0700190D0 (en) 2007-05-02
US6995272B2 (en) 2006-02-07
US6900334B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
DK0987256T3 (da) Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
DE69800430D1 (de) Modulatoren von durch Aminosäuren anregbare Rezeptoren
ID24247A (id) Penjajaran cetakan tunggal
DE69812007D1 (de) Aliphatische Lösungen von Aminoalkyllithiumverbindungen
DK0998473T3 (da) Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
IS5098A (is) Ný afbrigði af 2-amínó-4(4-flúorbensýlamínó)-1-etoxýkarbónýl-amínóbensen og aðferðir við framleiðslu þeirra
FI962932A7 (fi) Ankkuriproteiinifunktion modulaattoreita
DK38293D0 (da) Fremstilling af proteiner
ID28779A (id) BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
DK1533303T3 (da) Substituerede aminosalicylsyreamider (mellemprodukter)
DK0975217T3 (da) Synergistiske blandinger af udvalgte aminosyrer
ID21014A (id) Modifikasi kristal dari zat farmasi
FI960425A7 (fi) Fenyylisykloheksyylikarboksyylihappoamidien käyttö
DE69800559D1 (de) Ferrielektrische Flüssigkristallverbindung
DK1102747T3 (da) Krystalformer af osenetant
DK0823876T3 (da) Fremstilling af poser
CY2005003I2 (el) Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων
DK0980241T3 (da) Gelatineindkapslede opløsningsdosisformer af sertralin
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
DK1155004T3 (da) Fremgangsmåde til krystallisation af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK82592D0 (da) Fremstilling af proteiner
KR970027798U (ko) 시작 지그의 핀